NCT01986920View on ClinicalTrials.gov

Study of Safety, Tolerability and Effectiveness of A-101 in Subjects With Seborrheic Keratosis

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

35

Participants

Timeline

Start Date

October 22, 2013

Primary Completion Date

February 25, 2014

Study Completion Date

February 25, 2014

Conditions
Seborrheic Keratosis (SK)
Interventions
DRUG

A-101 25%

Low Dose Concentration of A-101 applied to one of 4 Target Lesions

DRUG

A-101 32.5%

Mid Dose Concentration of A-101 applied to one of 4 Target Lesions

DRUG

A-101 40%

High Dose Concentration A-101 applied to one of 4 Target Lesions

DRUG

A-101 Vehicle

Placebo applied to one of 4 Target Lesions

Trial Locations (1)

78759

DermResearch, Inc., Austin

Sponsors
All Listed Sponsors
lead

Aclaris Therapeutics, Inc.

INDUSTRY

NCT01986920 - Study of Safety, Tolerability and Effectiveness of A-101 in Subjects With Seborrheic Keratosis | Biotech Hunter | Biotech Hunter